Sangui BioTech:

- Granulox is awarded the prestigious Prix Galien

Hamburg, October 21, 2021: The wound spray Granulox developed by Sangui and licensed to Mölnlycke Health Care GmbH was awarded the Prix Galien for the best medical product of 2020 in Belgium and Luxembourg. The Prix Galien is awarded annually. The awards were created in France in 1970 by the pharmacist Roland Mehl in honor of Galen, the father of medical science and modern pharmacology. The Prix Galien honors the world's most innovative drugs and medical devices. It is considered the equivalent of the Nobel Prize in the pharmaceutical and medical industries.

"We congratulate the entire Mölnlycke team for this terrific success. The fact that the expert jury voted for Granulox, despite the nomination of medical products from such renowned manufacturers as Siemens Healthineers, BeWell Industries, Norgine and Sunrise, underscores and further validates the importance of the therapy for the healing of chronic wounds researched and developed by Prof. Dr. Dr. Wolfgang Barnikol and Dr. Harald Pötzschke. This award honors the commitment of everyone involved in this project - from basic research to successful market launch" Hubertus Schmelz, Managing Director of SanguiBio Tech GmbH, is delighted.

Link to the press release from Mölnlycke Health Care: https://www.molnlycke.com/news/molnlycke-news/granulox-wins-prix-galien/

Link to the video of the award ceremony: https://www.artsenkrant.com/actueel/uitreiking-galenusprijs-2020-winnaars-in-beeld/video-normal-57403.html?cookie_check=1634234307

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

For more information please contact:
Sangui Biotech International, Inc.
Thomas Striepe
Fax: +49 (40)46093120
e-mail: info@sangui.de

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.